DOCKET NUMBER
PETITION RULE PRM 35-9
(54FR38239)

(62)

October 18, 1989

'89 OCT 25 P3:52

Secretary of the Commission
U.S. Nuclear Regulatory Commission
Docketing and Service Branch, Docket # PRM-35-9
Washington, D.C. 20555

Dear Mr. Secretary:

I strongly support the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing Nuclear Medicine physician at Winthrop University Hospital in Mineola, New York. I am deeply concerned over the revised 10 CFR 35 regulations effective April, 1987 governing the medical use of byproduct material as they significantly effect my ability to practice high-quality Nuclear Medicine and are preventing me from providing optimized individual care.

For example, for therapeutic serivces you are forced to follow the instructions not only for kit preparation and expiration times, but also for FDA-approved indications, route of administration. activity levels etc.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Continued on Page II

WINTHROP-
UNIVERSITY HOSPITAL
MINEOLA, L.I., N.Y. 11501

DEPARTMENT OF
RADIOLOGY
Harold Chiat, M.D.
Chairman

DEPARTMENT OF
RADIATION THERAPY AND
NUCLEAR MEDICINE
(516) 663-2502
Perry R. Mandel, M.D.
Director
Bruce I. Saxe, M.D.
Co-Director
William Cheng, M.D.

IMAGING SERVICES
(516) 663-2501
Joseph A. Marotta, M.P.A.
Administrator

DEPARTMENT OF
MEDICAL PHYSICS
(516) 663-2501
James Summers, M.S.
Director
Robert Egger, M.S.
Richard McKeown, B.S.
Mark Belanich, M.S.
Debra Elder, A.A.S.

DIAGNOSTIC RADIOLOGY
(516) 663-2374
David Faegenburg, M.D.
Director
Seymour Cagan, M.D.
Raymond L. Saperstein, M.D.
Robert V. Blake, M.D.

ULTRASOUND
(516) 663-2377
Heywood Y. Epstein, M.D.
Director
Paul D. Cayea, M.D.

NEURORADIOLOGY AND
CT SCAN
(516) 663-2397
William J. Wortman, M.D.
Director

SCHOOL OF RADIOLOGY
(516) 663-2536
Virginia Edele
Director

DS10

Currently, the regulatory provisions in Part 35 (35,100, 35,200, 35,300 and 33.17 (a)(4) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

Finally, I would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal, studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspect of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and prepare these materials.

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NRCP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,

PM:mf

Perry R. Mandel, M.D.
Chief, Department of Radiation Therapy
and Nuclear Medicine.
Associate Professor of Clinical Radiology,
State University of New York

CC: Mr. James Summers,
Director of Nuclear Physics

Mr. Joseph Marotta,
Administrator, Imaging Services